Welcome to the e-CCO Library!

P496: Impact of ulcerative colitis on costs, work productivity and quality of life: a prospective study in a single referral centre
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Scrivo*1, A. F. Aiello2, E. Giuffrida2, V. Calvaruso2, M. Cappello2

Created: Friday, 22 February 2019, 9:41 AM
P496: Real-world outcomes of vedolizumab for inflammatory bowel disease post liver transplantation
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Peverelle*, C. Mills, A. Testro, P. de Cruz

Created: Thursday, 21 February 2019, 9:14 AM
P496: Successful dose de-escalation to adalimumab 40mg every three weeks in patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ferrante M.*1, Van Steenbergen S.1, Bian S.2, Ballet V.1, Vermeire S.1, Van Assche G.1, Gils A.2

Created: Wednesday, 20 February 2019, 10:36 AM
P497 Is mucosal healing sufficient paramater for anti-TNF discontinuation?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Knezevic1, M. Milic2, A. Kalaba1, S. Sreckovic1, B. Stopic3, P. Svorcan1, S. Markovic1

Created: Thursday, 30 January 2020, 10:12 AM
P497: Clinical features and outcomes of tuberculosis in inflammatory bowel disease patients treated with anti-TNF therapy as compared with the general population
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J. Kim*1, J. P. Im1, J.-J. Yim2, C. K. Lee3, D. I. Park4, C. S. Eun5, S.-A. Jung6, J.E. Shin7, K.-M. Lee8, J. H. Cheon9

Created: Friday, 22 February 2019, 9:49 AM
P497: Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis
Year: 2022
Source: ECCO'22
Authors: Sagami, S.(1,2);Kobayashi, T.(1);Aihara, K.(3);Umeda, M.(3);Odajima, K.(3);Morikubo, H.(1,2);Asonuma, K.(1);Miyatani, Y.(1);Fukuda, T.(1,2);Matsubayashi, M.(1,2);Kiyohara, H.(1,2);Nakano, M.(1,2);Hibi, T.(1);
Created: Friday, 11 February 2022, 3:56 PM
P497: IL-33/ST2 levels and gut microbiota characterisation can predict mucosal response to anti-TNF therapy in ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. R. Lopetuso*1, V. Petito1, C. Graziani1, A. Quagliariello3, F. Del Chierico3, L. Putignani3, T. T. Pizarro4, A. Armuzzi1, F. Scaldaferri1, A. Gasbarrini1

Created: Friday, 22 February 2019, 9:41 AM
P497: Impacts of mucosal healing on clinical outcomes in patients with refractory ulcerative colitis on tacrolimus or biologics
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Yamamoto T., Shimoyama T., Umegae S.

Created: Wednesday, 20 February 2019, 10:36 AM
P497: Injection site reactions and injection site pain for the adalimumab biosimilar ABP 501: Results from two double-blind, randomised, controlled studies
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Krishnan*, N. Zhang, H. Wang

Created: Thursday, 21 February 2019, 9:14 AM
P497: Is early bowel resection better than medical therapy for ileocolonic Crohn's disease? A systematic review and meta-analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Husnoo, N.(1);Gana, T.(2);Hague, A.G.(2);Khan, Z.(2);Morgan, J.L.(1);Wyld, L.(1);Brown, S.R.(2)*;
Created: Friday, 14 July 2023, 11:05 AM
P497: The value of endoscopic healing index monitoring for guiding infliximab dosing in patients with Crohn’s disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Kantasiripitak, W.(1);Mathôt, R.(2);Oldenburg, B.(3);Buisson, A.(4);Ferrante, M.(5,6);Laharie, D.(7);D’Haens, G.(8);Vermeire, S.(5,6);Dreesen, E.(1,9);
Created: Wednesday, 2 June 2021, 4:12 PM
P498 Loss of response of anti-TNF in Crohn’s disease patients single-centre experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Atanassova, A.C. Georgieva, M. Mirchev

Created: Thursday, 30 January 2020, 10:12 AM
P498: A nationwide quality improvement program in children with Crohn's disease improves outcomes within 12 months
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Turner*1, C. Nehemia1, A. Yerushalmy-Feler2, A. Assa3, M. Slae4, M. Kori5, Y. Elenberg6, R. Shaoul7, E. Zifman8, H. Shamaly9, D. Berkowitz10, S. Peleg11, B. Yerushalmi12, E. Broide13, A. Aon14, O. Elkayam15, H. Bayan16, A. Gorodnichenko17, V. Pinsk18, D. Shouval19

Created: Friday, 22 February 2019, 9:41 AM
P498: Crohn’s disease patient’s isolated classical monocytes are characterised by reduced secretion of Wnt-ligands affecting Paneth cell antimicrobial host defense
Year: 2018
Source: ECCO '18 Vienna
Authors:

N.S. Armbruster*, U. Denzau-Graupner, T. Klag, M. Götz, N. Malek, J. Wehkamp

Created: Thursday, 21 February 2019, 9:14 AM
P498: Diagnosing and differentiating iron deficiency in inflammatory disorders: still an unsolved mystery?
Year: 2021
Source: ECCO'21 Virtual
Authors: Aksan, A.(1,2);Aksan, S.(1,3);Farrag, K.(1);Schröder, O.(1,3);Stein, J.M.(1,3,4);
Created: Wednesday, 2 June 2021, 4:12 PM
P498: Emerging role of the IL-33/ST2 axis in predicting mucosal response to anti-TNF therapy in ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lopetuso L.R.*1,2, Petito V.3, Graziani C.3, Scannone D.4, Scaldaferri F.5, Pizarro T.T.6, Gasbarrini A.3

Created: Wednesday, 20 February 2019, 10:36 AM
P498: Rephrasing the question: a novel simple tool for a more accurate evaluation of inflammatory bowel disease patients’ adherence to therapy
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Engel*1, G. Ben-Haim2, N. Levhar1, R. Eliakim1, S. Ben-Horin1

Created: Friday, 22 February 2019, 9:49 AM
P498: Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess: The Leeds Steroids study
Year: 2022
Source: ECCO'22
Authors: Rosiou, K.(1);Carbonell, J.(1);Dolby, V.(1);Monfared, N.(1);Selinger, C.(1);
Created: Friday, 11 February 2022, 3:56 PM
P498: Ustekinumab Real World Evidence Study (UndieS): study design with information about positioning and the choice of ustekinumab
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Young, D.(1,2);Booker, C.(1);Samaan, M.(3);Limdi, J.(4,5);Kok, K.(6);Donovan, F.(7);Hart, A.(8);Smith, M.(9);Bodger, K.(10);Batchelor, J.(2);Cummings, F.(1,2)*;
Created: Friday, 14 July 2023, 11:05 AM
P499 Objectively assessed disease activity during ustekinumab treatment in a nationwide real-life Crohn’s disease cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C.G. af Björkesten1, T. Ilus2, T. Hallinen3, E. Soini3, A. Eberl1, K. Hakala4, M. Heikura5, E. Hirsi6, A. Jussila2, M. Kellokumpu7, R. Koskela8, I. Koskinen9, V. Moilanen10, C. Nielsen11, U. Nieminen1, H. Nuutinen12, M. Heikkinen13, U.M. Suhonen14, J. Tillonen15, K. Utriainen16, I. Vihriälä17, C. Wennerström18,19, A. Borsi20, R. Nissinen21, M. Koivunen21, T. Sipponen1

Created: Thursday, 30 January 2020, 10:12 AM